- Home
- CNTY vs BNTC Comparison
CNTY vs BNTC Comparison
Compare CNTY & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTY | BNTC |
|---|---|---|
| Founded | 1992 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0M | 454.2M |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CNTY | BNTC |
|---|---|---|
| Price | $1.17 | $11.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $3.00 | ★ $27.67 |
| AVG Volume (30 Days) | 31.1K | ★ 115.6K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.31 | 6.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $430,529,000.00 | N/A |
| Revenue This Year | $7.17 | N/A |
| Revenue Next Year | $3.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 10.82 | N/A |
| 52 Week Low | $1.14 | $9.85 |
| 52 Week High | $2.80 | $16.76 |
Technical Indicators
Market Signals| Indicator | CNTY | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 34.61 | 33.99 |
| Support Level | N/A | $10.04 |
| Resistance Level | $1.33 | $13.51 |
| Average True Range (ATR) | 0.03 | 0.68 |
| MACD | -0.01 | -0.18 |
| Stochastic Oscillator | 12.50 | 4.53 |
Price Performance
Historical ComparisonAbout CNTY Century Casinos Inc.
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurants, horse racing (including off-track betting), and entertainment facilities in North America. The company has five reportable segments based on the geographical locations in which its casinos operate; US East, US Midwest, US West, Canada, and Poland.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.